Fulgent (FLGT) Q1 2026 Earnings Transcript

Fulgent Genetics reported Q1 revenue of $71.1 million, down 3.2% year over year and 14.6% sequentially, as a large customer continued shifting testing in-house. Gross margin fell to 30.2% GAAP, adjusted EBITDA worsened to a $15.2 million loss, and management flagged further Q2 pressure before potential second-half stabilization. The company reaffirmed its 2026 revenue guide of $350 million while trimming EPS guidance to a $1.59 loss per share and highlighting $2.6 million in quarterly buybacks plus ongoing AI, pathology, and clinical pipeline initiatives.

Analysis

The core setup is not “temporary softness,” it is a customer-concentration unwind that creates a revenue air pocket exactly when the company is trying to re-rate as a diversified precision-diagnostics platform. The near-term risk is mechanical: lost high-margin volume plus slower claims conversion compresses gross margin and operating leverage faster than management can offset with mix or cost control. That means the next 1-2 quarters are likely to be driven more by cadence and collections than by underlying demand, which keeps estimate revisions vulnerable even if the full-year guide is technically intact.

The more interesting second-order effect is that buybacks are doing a lot of the lifting in the EPS story while also masking the fact that the business is consuming optionality. Repurchasing roughly 10% of shares while simultaneously paying for acquisitions and funding R&D leaves less room for error if the tax refund slips further or the large customer transition accelerates. In other words, capital return is supportive for per-share optics, but it increases balance-sheet sensitivity to execution misses over the next two quarters.

Strategically, the stock is being asked to bridge a gap between shrinking legacy volume and a set of newer growth vectors that are real but not yet scaled enough to matter in the near term. AI pathology, PGx reimbursement, and the expanded sales force are all plausible medium-term upside levers, but they likely need 2-4 quarters before they can offset the customer transition with visible consistency. The market is likely underpricing how long it takes for a sales-team integration to translate into billable volume, while overestimating how quickly the new tests can absorb the lost anchor customer business.

Contrarian view: the selloff may still be incomplete if investors are anchoring on annual guidance rather than quarterly earnings power. The upside case is that Q2 becomes the trough and back-half revenues accelerate on full-quarter acquisition contribution plus better claims conversion; the downside is that stabilization slips into 2027 and buybacks merely slow the per-share damage. This is a classic “good story, bad tape” situation where the story assets are improving faster than the P&L, but not fast enough to protect the next print.

Key Decisions for Investors

• Short FLGT into the next 1-2 earnings windows if the stock rallies on reiterated guidance; the setup favors another estimate reset before fundamental stabilization, with downside driven by gross-margin compression and customer loss cadence.
• For investors who want exposure to the optionality, buy FLGT only on post-earnings weakness after Q2 guidance is fully absorbed; this is a better entry than chasing buyback-driven EPS optics.
• Pair trade: long ILMN / short FLGT for a 3-6 month horizon if you want relative exposure to genome-platform monetization without single-customer risk; ILMN has cleaner operating leverage while FLGT is still in transition.
• Use FLGT downside puts into the next print if implied vol is not excessive; the catalyst path is asymmetric because a small change in Q2 revenue guidance can overwhelm the buyback-supported EPS narrative.
• If holding FLGT, set a hard risk stop if management sounds less confident about second-half stabilization or if cash guidance is revised again before the tax refund lands.